Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?

Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research • Jun 22, 2026

Here's How Macro Trends and Currency Headwind Restrict GMED's Growth

Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.

Zacks Investment Research • Jun 22, 2026

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Jun 22, 2026

Here's How Innovation Fuels Globus Medical's Growth Momentum

GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.

Zacks Investment Research • Jun 15, 2026

Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom

Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.

Zacks Investment Research • Jun 9, 2026

Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?

The consensus price target hints at a 38.9% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Jun 8, 2026

Here's Why Globus Medical (GMED) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 5, 2026

GMED or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jun 5, 2026

Here's How Financial Strength Remains a Key Advantage for GMED

Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.

Zacks Investment Research • Jun 4, 2026

Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?

Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.

Zacks Investment Research • Jun 2, 2026